Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

Next Previous
Trial Profile

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms NAVIGATOR
  • Sponsors Amgen; AstraZeneca

    • Most Recent Events

    • 07 Nov 2023 Results of pooled analysis from pooled analysis of the PATHWAY and NAVIGATOR , published in the Annals of Internal Medicine
    • 19 Sep 2023 Results assessing the effect of tezepelumab versus placebo on additional lung function parameters in patients from NAVIGATOR published in the Advances in Therapy
    • 13 Sep 2023 Results of post-hoc pooled analysis from PATHWAY (NCT02054130) and NAVIGATOR(NCT03347279) studies assessing the effect of tezepelumab on pre-BD ppFEV1 in patients grouped by baseline pre-BD ppFEV1 presented at the 33rd Annual Congress of the European Respiratory Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top